bit.bio

About bit.bio

bit.bio is a synthetic biology company focused on rewriting human health by programming human cells. Their mission is to create any human cell type at scale with precision and consistency, using cells as cures for research, drug discovery, and therapeutics.

Products & Services

ioCells:Deterministically programmed human iPSC-derived cells for research and drug discovery, including Wild Type Cells, Disease Model Cells, CRISPR-Ready Cells, and Tracker Cells.

ioWild Type Cells:Includes various cell types such as Glial Cells (Astrocytes, Microglia, Oligodendrocyte-like cells), Muscle Cells (Skeletal Myocytes), and Nerve Cells (GABAergic, Glutamatergic, Motor, Sensory Neurons).

ioDisease Model Cells:Cells modeled for diseases like ALS, FTD, Alzheimer's, Duchenne Muscular Dystrophy, Huntington's, Parkinson's, and Gaucher disease.

CRISPR-Ready ioCells:Cells designed for CRISPR applications, including activation, interference, and knockout-ready cells for various neuron and glial types.

ioTracker Cells:Cells with tracking capabilities, such as GFP-labeled Microglia and Glutamatergic Neurons.

Custom ioCells Development:Custom development of ioCells tailored to specific research needs.

Custom ioDisease Model Cells:Custom disease model cells for specific therapeutic research.

CRISPR Screening:Service for CRISPR-based screening to support research and drug discovery.

Cell Therapies:Therapeutic solutions derived from programmed cells with potential for next-generation therapies.

Early Access Program ioHepatocytes:A new iPSC-derived liver model available through an early access program.

Specialties

Human Cell Programming Synthetic Biology iPSC-derived Cells Cell Therapies Drug Discovery Disease Modeling CRISPR Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 50000000 MR: - FA: US$50 million FAN: 50000000	D: 2026-01-09 FD: 2026-01-09	1 investors

Series C Latest

2026-01-09

$50.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark Kotter

Canadian neurosurgeon, biologist, and entrepreneur

P

Przemek Obloj

CEO

R

Richard D. Klausner

Founder and Chief Scientist at Altos Labs

E

Emma Pepperell

VP Commercial

O

Orlaith Greenan

VP of Operations

T

Thomas Moreau

Precision Reprogramming Research

View 23 more team members with Pro

Unlock Full Team Directory

Recent News

bit.bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised